Name: EC Midday press briefing of 29/06/2026
Uploaded: 2026-06-29T10:47:29+00:00
Duration: 140 s

EC Midday press briefing of 29/06/2026

29 juin 2026

Sommaire mis à jour le 29 juin 2026

NHK asks about the EMA committee’s recommendation to revoke Tavneos (avacopan) and requests the Commission’s decision timeline and guidance for current patients; the Commission spokesperson explains Tavneos’ use for a rare autoimmune vasculitis, notes new scientific data led to the January review request, states that benefits are no longer proven, outlines that an accelerated procedure is now in place and that the Commission expects to take a final decision within about one month.

European Commission lun. 29 juin 2026 Commission européenne

00:00 - 00:30

Intervenant 2

Thank you, Sacha, from NHK, the Japanese TV station. Maybe it's for Eva, I'm not sure, but I would like to ask about the EMA's committee recommending to withdraw the approval of Tavneos or avacopan. Could you give us a timeline on when the next decision is to be made by the Commission and in the meantime, what is the Commission advising the patients currently going through this treatment? Thank you.

00:30 - 02:06

Intervenant 3

Thank you very much, Sacha, for the question. You know that we have European Medicines Agency and the Committee for Medicinal Products for Human Use of the EMA recommended to revoke the marketing authorization for Tavneos because at this stage we are not sure that there are benefits for the patients. It seems that there are no longer proven benefits for those who were using it. Just to explain what we are talking about, Tavneos is a medicine that is used for very rare disease. It's an autoimmune disease when the body affects basically the blood vessels.

And it was used usually in combination with other medicinal products. It's available only on prescription. We have requested to review this medicine already in January this year because we have obtained information and assessments from scientists that there are some new developments. So now we will put in place accelerated decision for the upcoming procedure. After the decision of the committee, now Commission needs to have a final say.

So we hope that the Commission will adopt the decision within one month.

La suite de la transcription est réservée aux clients Pro

Débloquez la transcription complète, le chat et toutes les fonctionnalités d'analyse avec Polyfact Pro.